VolitionRX Ltd to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014
Nov 24 14
VolitionRx Limited announced that data from its pilot lung cancer study will be presented at the Science for Business BioWin Day 2014, being held November 26, 2014 in Louvain-la-Neuve, Belgium. The data come from VolitionRx's lung cancer pilot study, the samples for which were collected at the Pneumology department of the Centre Hospitalier Universitaire (CHU) de Liege in Belgium. The study assessed the ability of VolitionRx's proprietary NuQ(R) platform to detect lung cancer in both blood and sputum (airway secretions, or mucus coughed up from the lower respiratory tract). Currently, most lung cancers are first diagnosed based on symptoms, which generally reflect damage to the lungs' ability to function normally. Unlike mammography for breast cancer or colonoscopy for colorectal cancer, a screening tool for early-stage lung cancer is not available beyond the American Society of Clinical Oncology's (ASCO) guidelines suggesting annual screening with a low-dose computed tomography scan (LDCT) for individuals at high risk for lung cancer[i]. A simple, accurate, cost-effective test could help detect lung tumors in their earliest stages, when many physicians believe the tumors are most curable. VolitionRx's prospective study tested both blood and sputum samples from 46 individuals with either non-small cell lung cancer, chronic obstructive pulmonary disease (COPD) or with no disease (healthy) across various NuQ(R) assay panels. In sputum samples, the analysis demonstrated that VolitionRx's NuQ(R) test was able to detect 18 of 21 lung cancer cases (85%) with no false positive results for healthy subjects (0 of 13). Furthermore, NuQ(R) assays were able to discriminate lung cancer from COPD, another important respiratory disease linked to habitual smoking. The sputum assay data is age and smoking independent. In blood samples from the same patients adjusted for age and smoking risk, the NuQ(R) assays were able to detect 16 of the 21 patients with cancer (76%) with a single false positive result for a healthy subject (1 of 13). This test was also able to discriminate lung cancer from COPD. Overall, the technology in both blood and sputum samples appeared to detect both early and late stage lung cancer with high sensitivity and specificity, but further research with a larger number of samples is required to confirm this outcome. The NuQ(R) tests utilize the Company's proprietary Nucleosomics(R) platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals within the blood, and now within sputum. In addition to this study, other clinical trials assessing the effectiveness of VolitionRx's assays include: A 4,800 patient retrospective symptomatic population study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. A 14,000 patient prospective screening study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany. A 250 patient prospective study in colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium. A retrospective study with MD Anderson, Texas, to establish the efficacy of VolitionRx's NuQ(R) tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form. A prospective study with the University of Oxford, United Kingdom, to assess VolitionRx's NuQ(R) tests for the diagnosis of endometriosis.
VolitionRX Ltd Presents at SeeThruEquity Fall Microcap Investor Conference 2014, Nov-12-2014 09:00 AM
Nov 5 14
VolitionRX Ltd Presents at SeeThruEquity Fall Microcap Investor Conference 2014, Nov-12-2014 09:00 AM. Venue: Convene Midtown East, New York, New York, United States. Speakers: Cameron Reynolds, Chief Executive Officer, President and Director.
VolitionRx Limited Announces Data Analysis from its Colorectal Cancer Study
Oct 9 14
VolitionRx Limited announced that further data analysis from its colorectal cancer study was presented on October 9, 2014 at the 9th International Conference of Anticancer Research. The data released comes from an initial representative 938-subject sample of VolitionRx's 4,800-subject colorectal cancer trial, and was presented at the session 'Diagnosis and Prognosis of Cancer' at conference. The company presented the new analysis of the sample from the ongoing, retrospective study taking place at Hvidovre Hospital, Denmark, to evaluate the ability of the company's NuQ(r) blood-based diagnostic platform to detect colorectal cancers. These findings go beyond the initial topline data recently announced during the Aegis Capital 2014 Healthcare &Technology Conference, which demonstrated that the NuQ(r) diagnostic test detects 84% of colorectal cancers at 78% specificity, and 60% of polyps, in a population aged over 50 years with symptoms indicative of colorectal cancer. The findings include data analysis performed for 830 of the first 938 subjects tested, as analysis was restricted to subjects greater than 50 years of age on whom all the tests were completed. Among the 830 subjects, a total of 59 colorectal cancer cases were identified by colonoscopy, including 35 colon cancer and 24 rectal cancer cases. Of the 59 colorectal cancer cases, the NuQ(r) blood test was able to detect both early (I or II) and late (III or IV) stage cases with high accuracy.